COVI-VAC is under clinical development by Codagenix and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how COVI-VAC’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
COVI-VAC overview
COVI-VAC is under development for the prevention of coronavirus disease 2019 (COVID-19). The vaccine candidate is being developed based on synthetic attenuated virus engineering (SAVE) technology which uses viral deoptimization to synthesize live-attenuated vaccines. It is administered by intranasal route.
Codagenix overview
Codagenix operates as a clinical-stage synthetic biology company. The Company offers vaccine and oncology programs against COVID-19. The company is headquartered in the United States.
For a complete picture of COVI-VAC’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
